HomeCompareBOVNF vs MO

BOVNF vs MO: Dividend Comparison 2026

BOVNF yields 60.82% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BOVNF wins by $598.0K in total portfolio value
10 years
BOVNF
BOVNF
● Live price
60.82%
Share price
$3.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$678.1K
Annual income
$160,128.39
Full BOVNF calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — BOVNF vs MO

📍 BOVNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBOVNFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BOVNF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BOVNF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BOVNF
Annual income on $10K today (after 15% tax)
$5,169.37/yr
After 10yr DRIP, annual income (after tax)
$136,109.13/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, BOVNF beats the other by $110,473.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BOVNF + MO for your $10,000?

BOVNF: 50%MO: 50%
100% MO50/50100% BOVNF
Portfolio after 10yr
$379.1K
Annual income
$95,143.77/yr
Blended yield
25.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

BOVNF
No analyst data
Altman Z
10.4
Piotroski
3/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BOVNF buys
0
MO buys
0
No recent congressional trades found for BOVNF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBOVNFMO
Forward yield60.82%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$678.1K$80.1K
Annual income after 10y$160,128.39$30,159.17
Total dividends collected$563.7K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: BOVNF vs MO ($10,000, DRIP)

YearBOVNF PortfolioBOVNF Income/yrMO PortfolioMO Income/yrGap
1← crossover$16,782$6,081.62$10,570$780.30+$6.2KBOVNF
2$27,495$9,538.25$11,381$1,032.90+$16.1KBOVNF
3$44,024$14,604.90$12,535$1,392.73+$31.5KBOVNF
4$68,961$21,855.37$14,193$1,920.91+$54.8KBOVNF
5$105,784$31,995.46$16,618$2,723.68+$89.2KBOVNF
6$159,058$45,869.04$20,263$3,993.80+$138.8KBOVNF
7$234,649$64,457.18$25,936$6,098.36+$208.7KBOVNF
8$339,944$88,869.20$35,166$9,775.01+$304.8KBOVNF
9$484,065$120,324.94$51,026$16,597.78+$433.0KBOVNF
10$678,078$160,128.39$80,113$30,159.17+$598.0KBOVNF

BOVNF vs MO: Complete Analysis 2026

BOVNFStock

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

Full BOVNF Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this BOVNF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BOVNF vs SCHDBOVNF vs JEPIBOVNF vs OBOVNF vs KOBOVNF vs MAINBOVNF vs PMBOVNF vs BTIBOVNF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.